DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20190459

Evaluation and comparison of anti-cancer activity of dapagliflozin and canagliflozin in oral cancer cell line: an in vitro study

Nenavath Vinay, Darling Chellathai David

Abstract


Background: Cancer is rapidly evolving life-threatening ailment in the mankind due to changes in daily food intake and lifestyle changes. Oral carcinoma is 6th major cause of cancer death in the world and it is third major reason of cancer mortality in India. Every cell in the human body requires glucose for its metabolic energy. Besides normal cell, cancer cells also require the glucose for its endurance and multiplication. SGLT2 inhibitors which are aimed at diabetes therapy exhibited anticancer properties also in colon and pancreatic cancer lines. Present study aim is to evaluate the anticancer activity of SGLT2 inhibitors against oral cancer cell by MTT Assay.

Methods: To evaluate the anticancer activity of SGLT2 inhibitors MTT Cytotoxic assay is performed as per standard protocols. Cancer cells were plated in 24-well plates and incubated at 370C with 5% CO2 condition. After convergence, samples are added to the plates in various concentrations and allowed to incubate then they are detached from the plates and cleansed with the reagents. The wells are coated with the dye and incubated. Later samples are analysed in UV-spectrophotometer.

Results: Cytotoxic assay showed decrease in cell viability with increasing dose of SGLT2 inhibitors. IC50 values were determined graphically. The IC50 value of dapagliflozin is 400µg/ml and canagliflozin is 250µg/ml respectively after 24 hours of Assessment.

Conclusions: The results of the current study give us an evidence that SGLT2 inhibitors dapagliflozin and canagliflozin exhibits anticancer property in Oral Cancer cell line.


Keywords


Canagliflozin, Dapagliflozin, Oral cancer, MTT Assay, SGLT2 inhibitors

Full Text:

PDF

References


World Health Organization. Fact sheet: Cancer, 12 September 2018. Available at: https://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed 19 December 2018.

Gupta N, Gupta R, Acharya AK, Patthi B, Goud V, Reddy S, et al. Changing Trends in oral cancer-a global scenario. Nepal J Epidemiol. 2016 Dec;6(4):613.

Mallath MK, Taylor DG, Badwe RA, Rath GK, Shanta V, Pramesh CS, et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014 May 1;15(6):e205-12.

Auluck A. Diabetes mellitus: an emerging risk factor for oral cancer?. J Canadian Dental Assoc. 2007;73(6):501-3.

Rao SV, Mejia G, Roberts-Thomson K, Logan R. Epidemiology of oral cancer in Asia in the past decade-an update (2000-2012). Asian Pacific J Cancer Prevention. 2013;14(10):5567-77.

Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 1835;2013:164-9.

Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014 Dec 28;355(2):176-83.

Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Disposition. 2010 Mar 1;38(3):405-14.

Li LT, Zhou LF, Li YJ, Huang J, Liu RH, Wang B, et al. Facile synthesis of 1, 2, 3-triazole analogs of SGLT2 inhibitors by ‘click chemistry’. Bioorganic Medicinal Chem Lett. 2012 Jan 1;22(1):642-4.

Angelopoulou A, Voulgari E, Kolokithas-Ntoukas A, Bakandritsos A, Avgoustakis K. Magnetic Nanoparticles for the Delivery of Dapagliflozin to Hypoxic Tumors: Physicochemical Characterization and Cell Studies. AAPS Pharm Sci Tech. 2018 Feb 1;19(2):621-33.

Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proceed National Acad Sci. 2015 Jul 28;112(30):E4111-9.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:5563.

Saito T, Okada S, Yamada E, Shimoda Y, Osaki A, Tagaya Y, et al. Effect of dapagliflozin on colon cancer cell [rapid communication]. Endocrine J. 2015;62(12):1133-7.

Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Molecular Metabolism. 2016 Oct 1;5(10):1048-56.

Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Therapeutics. 2009 Jan 1;121(1):29-40.

Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013 Apr;1835(2):164-9.

Amy SY, Hirayama BA, Timbol G, Liu J, Basarah E, Kepe V, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010 Dec;299(6):C1277.

Amy SY, Hirayama BA, Timbol G, Liu J, Diez-Sampedro A, Kepe V, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013 Feb 1;304(3):C240.

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013 May 29.

Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012 Apr 27;149(3):656-70.

Shivpuje P, Ammanangi R, Bhat K, Katti S. Effect of ocimum sanctum on oral cancer cell line: an in vitro study. J Contemp Dental Practice. 2015 Sep;16(9):709-14.